29 November 2023
29 November 2023
Candel has fired 50% of its workforce and directed its resources to advance the development of CAN-2409 and CAN-3110.
As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.
V116 demonstrated a safety profile in line with PCV20 for both cohorts of the trial.
Opening the first day of the CTO Europe conference, experts set their sights on the impact of digital technologies on oncology trials.
ETH47 is Ethris’ first candidate to enter clinical trials, with an expected trial initiation date in December 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
